{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63"}],"title":"Number of Participants with an MRD Negative Complete Remission after Initial CAR T Infusion"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Number of Participants without an MRD Negative Complete Remission after Initial CAR T Infusion"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"description":"The efficacy of the T cell infusion will be estimated based on the number of participants who have an MRD negative bone marrow aspirate following the initial T cell infusion","groups":[{"description":"Efficacy-evaluable leukemia patients who received SCRIv1 or SCRIv1.5 CAR T cells","id":"OG000","title":"SCRI-CAR19v1/v1.5 Efficacy-evaluable Leukemia Cohort"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Efficacy-evaluable leukemia patients in Phase 2, plus Phase 1 patients treated at the Phase 2 dose in cohort 1F2, who received SCRIv1 or SCRIv1.5 CAR T cells following prescribed lymphodepletion with fludarabine and cyclophosphamide","reportingStatus":"POSTED","timeFrame":"Initial CAR T cell infusion through Day 63 post infusion assessment (+/- 14 days)","title":"Number of Participants With an MRD Negative Complete Remission After Initial CAR T Cell Infusion","type":"PRIMARY","unitOfMeasure":"Participants"}